Get access

PRRT2 mutation screening in patients with paroxysmal kinesigenic dyskinesia from Southwest China

Authors

  • Y. P. Chen,

    1. Department of Neurology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, SiChuan University, Chengdu, China
    Search for more papers by this author
    • Y. P. C. and W.S. contributed equally to this study.
  • W. Song,

    1. Department of Neurology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, SiChuan University, Chengdu, China
    Search for more papers by this author
    • Y. P. C. and W.S. contributed equally to this study.
  • J. Yang,

    1. Department of Neurology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, SiChuan University, Chengdu, China
    Search for more papers by this author
  • Z.-Z. Zheng,

    1. Department of Neurology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, SiChuan University, Chengdu, China
    Search for more papers by this author
  • R. Huang,

    1. Department of Neurology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, SiChuan University, Chengdu, China
    Search for more papers by this author
  • K. Chen,

    1. Department of Neurology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, SiChuan University, Chengdu, China
    Search for more papers by this author
  • B. Zhao,

    1. Department of Neurology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, SiChuan University, Chengdu, China
    Search for more papers by this author
  • X. P. Chen,

    1. Department of Neurology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, SiChuan University, Chengdu, China
    Search for more papers by this author
  • J.-M. Burgunder,

    1. Department of Neurology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, SiChuan University, Chengdu, China
    2. Department of Neurology, University of Bern, Bern, Switzerland
    Search for more papers by this author
  • H.-F. Shang

    Corresponding author
    1. Department of Neurology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, SiChuan University, Chengdu, China
    • Correspondence: H.-F. Shang, Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China (tel.: 0086 028 85423831; fax: 0086 028 85423550; e-mail: hfshang@yahoo.com).

    Search for more papers by this author

Abstract

Background and purpose

Proline-rich transmembrane protein 2 (PRRT2) has recently been identified as a causative gene of paroxysmal kinesigenic dyskinesia (PKD). However, the frequencies of its mutations and their correlation with the clinical features of PKD remain largely unknown.

Methods

Four exons of PRRT2 in 33 patients with PKD from Southwest China were screened by direct sequencing in this study.

Results

The mean onset age of the patients was 12.50 ± 2.70 years. Sixteen patients (48.48%) had sensory aura before their attacks. In total, 66.67% of the patients were running when the attacks occurred. c.649_650insC (p.P217fsX7), the most commonly reported insertion mutation, was identified in nine patients (27.27%).

Conclusions

Other genes are involved in the development of PKD, but PRRT2 is a common causative gene for patients with PKD from Southwest China.

Ancillary